Professional Documents
Culture Documents
Vol. 7, No. 4
Vol. 7, No. 4
October-December, 2006
Renal loss of potassium
Diet lacking in potassium
High-carbohydrate or high-salt meals
After intake of alcohol
Rest after heavy and unaccustomed exercise
Certain drugs such as diuretics, laxatives, insulin
therapy, Amphotericin B, -adrenergic
antagoni sts, -2 agoni sts, steroi ds
(glucocorticoids as well as mineralocorticoids),
penicillin and its derivatives, etc.
The episodes, hence, can be prevented by taking
low carbohydrate, low salt, and potassium rich diet
including fruit juices. The diuretics, if the patient is
taking for some other disorder, must be stopped
and replaced with other potassium-sparing
diuretics, if needed. Abstinence of alcohol should
always be recommended.
Q. 5. Do the paralytic attacks have any
relation to season or time?
Ans: Yes, the attacks appear to have seasonal variation,
usually occurring during the warmer months (May
through September in our country) and less often
during the colder months (December through
March). The paralysis also follows a diurnal pattern,
often occurring at night when the person is resting
in bed
8
. It does not occur when the person is
performing any physical activity.
Q. 6. What are the common conditions
simulating periodic paralysis?
Ans: The following are the common conditions which
simulate periodic paralysis. Their clinical
differentiation is tabulated (Table II).
Table II: Common conditions simulating periodic
paralysis.
1. Guillain-Barr The weakness in Guillain-Barr
syndrome syndrome follows some infection
(post-infectious) in 60% of the
cases and it lasts for several weeks;
whereas hypokalaemic thyrotoxic
periodic paralysis is a transient
condition lasting from hours to
days. The cerebrospinal fluid (CSF)
is characteristic in Guillain-Barr
syndrome, showing increased
protein content with few or no
cells (albumino-cytological
dissociation) while it is normal in
hypokalaemic thyrotoxic periodic
paralysis.
2. Polymyositis Pol ymyosi ti s i s frequentl y
associated with malignancies and
is characterised by elevated
creatinine kinase (CK) levels and
abnormal electromyography
(EMG). Polymyositis is usually a
diagnosis by exclusion.
3. Myasthenia gravis An acquired autoimmune disorder
in which autoantibodies (IgG) are
produced against acetylcholine
receptors at neuromuscular
j uncti ons; Ocul ar muscl es
weakness is characteristic. The
di agnosi s i s confi rmed by
electromyography (EMG) and
serological tests for the presence
of acetyl chol i ne receptor
antibodies.
4. Spinal cord These cases present with definite
compression focal neurological deficit involving
motor, sensory, and bladder
functions which is progressive.
There is a definite level reflecting
the si te of compressi on.
Radi ol ogi cal i magi ng (CT
myel ogram) confi rms the
diagnosis.
5. Andersen An autosomal disorder with
syndrome mutation in potassium channel
and it is characterised by periodic
paralysis and distinct facial
features with short stature, low-
set ears, hypertelorism, and long
QT interval predisposing to
ventricular tachyarrhythmia.
Journal, Indian Academy of Clinical Medicine
Vol. 7, No. 4
Vol. 7, No. 4
October-December, 2006
of 11-HSDH (hydroxy steroid dehydrogenase)
which ultimately leads to mineralocorticoid
excess and hypokalaemia. Liquorice root toxicity
following prolonged ingestion leads to periodic
paralysis.
6. Thyroid hormone abusers: Thyroid hormone
drives potassium into cells via sodium-
potassium ATPase pump and leads to
hypokalaemia. Iatrogenic use by obese patients
with intention to lower their weight may
predispose them to it.
Q. 8. How will you confirm the diagnosis?
Ans: The diagnosis of hypokalaemic thyrotoxic
periodic paralysis is confirmed by clinical and
biochemical evidence of thyrotoxicosis and
hypokalaemia with or without an abnormal
electrocardiogram (ECG) during the attacks.
Electromyography (EMG) is confirmatory and
shows electrical silence during attacks
10
. Muscle
biopsy occasionally may show abnormality.
Molecular genetic testing identifies the mutation
in the disease causing gene (KCNE 3)
11
.
Q. 9. How will you treat such a patient?
Ans: The aims of treatment are:-
1. To treat the acute episode and to prevent its
further episodes;
2. To normalise the serum potassium levels.
The treatment of hypokalaemia is determined by
severity of symptoms, serum potassium levels, and
the ECG changes, if any. Accordingly, the cases can
be managed as:
Mild hypokalaemia (3 - 3.5 mmol/l): Oral
potassium supplements in the form of potassium
chloride 30 to 100 mmol/day are adequate and
given with juice and at meals.
Moderate hypokalaemia (2.5 - 3.0 mmol/l):
Initially these cases are managed with oral
potassium supplements, and if the patient still
remains symptomatic then 10 mmol of potassium/
hour is started intravenously in 5% mannitol (avoid
glucose and saline as diluent) with cardiac
monitoring and serum potassium levels
monitoring.
Moderately severe hypokalaemia (2 - 2.5
mmol/l): Oral potassium supplements if tolerated
by the patient are given, and if there is no
improvement in 1 to 2 hours then 15 mmol of
potassium per hour is given intravenously in 5%
mannitol with continuous monitoring of cardiac
system and serum potassium concentrations.
Severe hypokalaemia (< 2 mmol/l): Oral
potassium replacement if tolerated by the patient.
In addition, administer upto 20 mmol of potassium
per hour intravenously in 5% mannitol with
continuous cardiac and serum potassium
concentration monitoring.
In the present case, the patient having serum
potassium concentration 2.1 mEq/l was treated as
a case of moderately severe hypokalaemia with
intravenous potassium infusion.
Q. 10. How will you prevent such attacks?
Ans: Prevention of attacks: Preventive treatment is
aimed at decreasing the frequency of symptoms
and paralytic attacks; therefore, the patient is
advised to take oral potassium supplements 20 -
40 mEq/day in 2 to 4 divided doses which are
available as potassium acetate, potassium chloride,
potassium bicarbonate, potassium citrate, and
potassium gluconate, etc. In patients with
hypokalaemia and metabolic alkalosis, the
supplement is given in the form of potassium
chloride, whereas in patients with hypokalaemia
and metabolic acidosis as in d-RTA/type-I RTA (renal
tubular acidosis), potassium gluconate, potassium
citrate, and potassium bicarbonate are the
preferred choice. In addition, the underlying
aetiological or precipitating factor must be
identified and treated/avoided. Acetazolamide is
highly effective in individuals with familial/primary
periodic paralysis; whereas in individuals with
thyrotoxic periodic paralysis; it is not found to be
Journal, Indian Academy of Clinical Medicine
Vol. 7, No. 4